Home > Boards > US OTC > Miscellaneous > Kannalife Inc. (KLFE)
Dean14
And Then 2
Posts 411
Boards Moderated
Alias Born 06/14/18
KLFE
Current Price
Volume:
KLFE Detailed Quote
Current Report Filing (8-k) Edgar (US Regulatory) – 3/18/2020 5: 05: 13 PM
Current Report Filing (8-k) Edgar (US Regulatory) – 1/28/2020 9: 01: 16 AM
Statement of Alterations in Beneficial Ownership (4) Edgar (US Regulatory) – 12/3/2019 3: 47: 50 PM
Quarterly Report (10-q) Edgar (US Regulatory) – 11/13/2019 5: 16: 10 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) – 8/14/2019 10: 52: 16 AM
Quarterly Report (10-q) Edgar (US Regulatory) – 8/13/2019 12: 48: 10 PM
Notice of Effectiveness (results) Edgar (US Regulatory) – 8/13/2019 6: 00: 43 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) – 8/8/2019 2: 07: 28 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) – 7/30/2019 11: 19: 33 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) – 7/5/2019 12: 18: 40 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) – 6/17/2019 1: 54: 14 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) – 5/23/2019 2: 53: 01 PM
Quarterly Report (10-q) Edgar (US Regulatory) – 5/14/2019 2: 13: 44 PM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) – 4/9/2019 1: 52: 41 PM
Annual Report (10-k) Edgar (US Regulatory) – 4/9/2019 1: 49: 06 PM
Notification That Annual Report Are Going To Be Submitted Late (nt 10-k) Edgar (US Regulatory) – 4/1/2019 3: 54: 58 PM
Dean14 Thursday, 01/23/20 09: 10: 12 AM
Re: None
Post # of 34
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Issues Update on Intellectual Property and Newly Acquired Patents
9: 00 AM ET 1/23/20 | Dow Jones
SAN DIEGO, Jan. 23, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the 1st-at any time openly dealt cannabis company in the us that released the world’s first-previously marijuana-derived nutraceutical items, give and companies chain, introduced today that its collection financial investment securities (https://prlog.ru/) provider Kannalife, Inc. (“Kannalife”) (OTC: KLFE) fairly recently given an revise on its intellectual home revolving all around its universal WIPO/PCT Patent WO2015/106108A2 titled “Novel Functionalized 1,3-Benzene Diols and their Procedure for Use for the management of Hepatic Encephalopathy” (the “PCT Patent”).
“Our company is very proud to get Kannalife as part of our investment decision account since they are continually getting to new milestones in exploring cannabinoid therapeutics,” explained Medical Marijuana, Inc. CEO Dr. Stuart Titus. “How much investigation during this area has risen significantly in the last year or so there is however however essential growth being made. It’s stimulating to check out Kannalife the main thing on this.”
For the reason that submitting with the PCT Patent in 2015, Kannalife has gotten patent authorization during the adhering to areas: U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols together with their Approach to Use for the treating of Hepatic Encephalopathy,” U.S. Patent 10,004,722 “Solution for getting rid of hepatic encephalopathy or simply a condition connected to cost-free major mediate stress and anxiety and oxidative pressure with creative functionalized 1,3-benzene diols,” Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols in addition to their Way of Use for the management of Hepatic Encephalopathy” and Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols and also their Way of Use for dealing with Hepatic Encephalopathy.”
Additionally, Kannalife’s app for patent defense of the mental property continues to be acknowledged inside the European Union (EU), China, and Australia. This Company is awaiting recognize from Brazil, India and Canada for observe of recognition. This Company anticipates sales receipt of patent grants through the Australia, EU and The far east someday over the next and initial quarters of 2020.
“If we registered our patent application for ‘Novel Functionalized 1,3-Benzene Diols together with their Method of Use for the management of Hepatic Encephalopathy,’ we decided everything you think being by far the most viable pharmaceutical drug markets for relocating our compounds into clinical trials,” reported Dean Petkanas, CEO of Kannalife. “An added patents we now have acquired can help us attain those aims in more trading markets.”
Currently, Kannalife’s top medication candidate KLS-13019, a cannabidiol (CBD)-like molecule has been investigated in pre-clinical tests to the probable management of neuropathic discomfort. Through considerable testing, Kannalife has identified a effective, no-opioid alternative to popular the frontline therapy of chemotherapy-induced peripheral neuropathy (CIPN).
About Medical Marijuana, Inc.
We are an agency of firsts. Medical Marijuana, Inc. (MJNA) is really a cannabis organization with a few specific organization systems within the no-psychoactive cannabinoid space: a global profile of cannabinoid-dependent nutraceutical makes led by HempMeds and Kannaway a leader in tracking down the top-high quality lawful non-psychoactive cannabis merchandise derived from commercial hemp plus a cannabinoid-centered professional medical exploration and organic drug progression market brought by its inside R&D and controlled team as well as its prescription expense spouses and companies as well as AXIM Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was called a top-notch CBD manufacturer by CNBC. Medical Marijuana, Inc. seemed to be the primary provider to acquire historical transfer allows for CBD solutions in the governments of Brazil,Mexico and Argentina, and Paraguay and it is a frontrunner in the development of overseas sells. Medical Marijuana, Inc.’s headquarters is San Diego, Ca, California, and extra details are offered by OTCMarkets.com or by visiting www.medicalmarijuanainc.com.
To determine Medical Marijuana, Inc.’s corporation video clip, click the link.
About KLS-13019
KLS-13019 is Kannalife’s top rated exclusive investigational CBD-like merchandise for the likely treatment of various neurodegenerative and neuropathic suffering issues, beginning with radiation treatment-caused peripheral neuropathy (CIPN). KLS-13019 is not evaluated or accepted for patient use with the U.S. Substance and Meal Administration (FDA) as well as other medical care expert worldwide. Its efficiency and security have not been affirmed by FDA-accepted analysis.
About Kannalife, Inc.
Family Office – A.D. Financial Sdn. Bhd.
www.adfinancial.com.my › services › family-office
A family office is dedicated to providing families with centralised support in managing their wealth to enable it to endure over several generations. What is a Family …
Kannalife, Inc. is often a biopharmaceutical business focused on the development of amazing and branded cannabidiol (CBD) and CBD-like molecules for individuals troubled with unmet health wants of neurodegenerative problems – including chemo-caused peripheral neuropathy (CIPN), a persistent neuropathy attributable to poisonous chemotherapeutic products hepatic encephalopathy (HE), a neurotoxic human brain-liver ailment a result of abnormal concentrations of ethanol and ammonia on the neurological minor disturbing head harm (mTBI), a disorder connected to individual and repeating impact traumas and long-term traumatic encephalopathy (CTE) an illness connected to really repeated influence traumas in specialist and amateur sporting events.
The Company’s family of amazing molecules is focused on treating oxidative tension-linked health conditions for example HE, persistent agony from neuropathies like CIPN, and neurodegenerative conditions like CTE. Kannalife conducts its exploration and creation attempts with the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
FORWARD-LOOKING DISCLAIMER
This touch release might have particular in front-looking data and claims, as characterized throughout the concept of Section 27A of your Securities Act of 1933 and Section 21E on the Securities Exchange Act of 1934, and its subject to the Safe Harbor designed by all those pieces. This product features statements about envisioned upcoming occasions and/or economical final results which can be frontward-searching in theme and aspect to uncertainties and threats. Such frontward-searching phrases obviously include other, uncertainties and risks aspects, which may cause the genuine success, efficiency or results of Medical Marijuana, Inc. being materially distinct from the phrases designed herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These claims have not been looked at via the Food and Drug Administration. This supplement is not really meant to cure, detect and take care of or stop any disease.